Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R ²) in Patients with Relapsed/Refractory Folli

11 hours ago 1

1. Homepage
2. Finance
3. Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R ²) in Patients with Relapsed/Refractory Folli